Randomized Placebo Control Study of Insulin Sensitizers (Metformin and Pioglitazone) in Psoriasis Patients with Metabolic Syndrome (Topical Treatment Cohort)

Overview

Journal BMC Dermatol

Publisher Biomed Central

Specialty Dermatology

Date 2016 Aug 18

PMID 27531132

Citations 25

Authors

Surjit Singh

Anil Bhansali

Affiliations

Soon will be listed here.

Abstract

Background: Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).

Methods: Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.

Results: Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values - PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values - PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value - PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue - PASI = 0.001, ESI = 0.001). Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.

Conclusion: Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.

Trial Registration: CTRI Registration Number: CTRI/2011/12/002252 . Registered on 19/12/2011.

Citing Articles

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas.

Chen W, Lin T, Chang Y, Shen Y, Hsu H, Kuo T Clin Transl Sci. 2025; 18(3):e70177.

PMID: 40075548 PMC: 11903325. DOI: 10.1111/cts.70177.

Exploring the Effects of Metformin on the Body via the Urine Proteome.

Chen Y, Wang H, Yang M, Shen Z, Gao Y Biomolecules. 2025; 15(2).

PMID: 40001544 PMC: 11853151. DOI: 10.3390/biom15020241.

Efficacy and safety of various drug combinations in treating plaque Psoriasis: A meta-analysis.

Snehasis N, Zafar S, Herve N, Siri P, Haji Ali K F1000Res. 2025; 13:453.

PMID: 39925996 PMC: 11803402. DOI: 10.12688/f1000research.149172.1.

Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial.

Guo L, Wang L, Tian D, Xu F, Huang W, Wu X Diabetes Ther. 2024; 15(11):2351-2366.

PMID: 39283411 PMC: 11466946. DOI: 10.1007/s13300-024-01638-y.

Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.

Mehta H, Narang T, Dogra S, Handa S, Hatwal J, Batta A Vasc Health Risk Manag. 2024; 20:215-229.

PMID: 38745849 PMC: 11093123. DOI: 10.2147/VHRM.S464471.

References

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

Rosenblatt S, Miskin B, Glazer N, Prince M, Robertson K . The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001; 12(5):413-23. DOI: 10.1097/00019501-200108000-00011. View

Malhotra S, Bansal D, Shafiq N, Pandhi P, Kumar B . Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis. Expert Opin Pharmacother. 2005; 6(9):1455-61. DOI: 10.1517/14656566.6.9.1455. View

COHN G, Valdes G, Capuzzi D . Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep. 2001; 3(5):416-23. DOI: 10.1007/s11886-001-0059-0. View

Wannamethee S, Shaper A, Lennon L, Morris R . Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165(22):2644-50. DOI: 10.1001/archinte.165.22.2644. View

Wallace T, Levy J, Matthews D . An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med. 2004; 21(6):568-76. DOI: 10.1111/j.1464-5491.2004.01218.x. View

Tseng C . Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012; 35(2):278-80. PMC: 3263866. DOI: 10.2337/dc11-1449. View

Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V . Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005; 112(18):2792-8. DOI: 10.1161/CIRCULATIONAHA.105.535484. View

. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995; 310(6972):83-8. PMC: 2548496. View

10.

Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M . Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298(7):321-8. DOI: 10.1007/s00403-006-0703-z. View

11.

Pershadsingh H, SPROUL J, Benjamin E, Finnegan J, Amin N . Treatment of psoriasis with troglitazone therapy. Arch Dermatol. 1998; 134(10):1304-5. DOI: 10.1001/archderm.134.10.1304. View

12.

Lewis J, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry Jr C . Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34(4):916-22. PMC: 3064051. DOI: 10.2337/dc10-1068. View

13.

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

14.

Demerjian M, Man M, Choi E, Brown B, Crumrine D, Chang S . Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 2006; 15(3):154-60. DOI: 10.1111/j.1600-0625.2006.00402.x. View

15.

Sterry W, Strober B, Menter A . Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007; 157(4):649-55. DOI: 10.1111/j.1365-2133.2007.08068.x. View

16.

Misra A, Wasir J, Pandey R . An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care. 2005; 28(2):398-403. DOI: 10.2337/diacare.28.2.398. View

17.

Wilson P, DAgostino R, Parise H, Sullivan L, Meigs J . Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112(20):3066-72. DOI: 10.1161/CIRCULATIONAHA.105.539528. View

18.

Mehnert H . Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S259-64. DOI: 10.1055/s-2001-18587. View

19.

Koca R, Altinyazar H, Yenidunya S, Solak Tekin N . Psoriasiform drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J. 2003; 9(3):11. View

20.

Patel R, Shelling M, Prodanovich S, Federman D, Kirsner R . Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011; 26(9):1036-49. PMC: 3157521. DOI: 10.1007/s11606-011-1698-5. View